Literature DB >> 26164770

More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life.

Cornelie D Andela1, Nienke R Biermasz1, Adrian A Kaptein2, Alberto M Pereira1, Jitske Tiemensma3.   

Abstract

OBJECTIVE: Patients with acromegaly can be treated with surgery, radiotherapy and/or medical treatment. In general, patients' beliefs about medication are associated with illness perceptions, a contributory factor of Quality of Life (QoL). At present, there are no quantitative studies on medication beliefs in patients with acromegaly. Here, we aimed to examine possible associations between medication beliefs, illness perceptions, and QoL. Furthermore we aimed to explore whether illness perceptions of patients with remission of acromegaly receiving medical treatment differ from patients without medical treatment.
DESIGN: Cross-sectional evaluation of 73 patients with remission of acromegaly (n = 28 patients with medication, n = 45 without medication). The Beliefs about Medicines Questionnaire (BMQ), Illness Perception Questionnaire-Revised (IPQ-R), EuroQoL-5D, and AcroQoL were used for the assessment.
RESULTS: Stronger beliefs about the necessity of medical treatment and stronger concerns about the adverse effects were associated with attributing more symptoms to acromegaly, perceiving more negative consequences, and having a stronger belief in a cyclical timeline (BMQ, all P < 0.05). Stronger beliefs about the necessity of medical treatment were associated with a worse disease-specific QoL (BMQ, P < 0.01). Patients with medical treatment perceived a more chronic timeline of their disease, compared to patients without medical treatment (IPQ-R, P = 0.002).
CONCLUSION: Negative medication beliefs were related to more negative illness perceptions and worse disease-specific QoL. Patients receiving medical treatment for acromegaly tend to perceive a more chronic timeline of their disease, compared to patients with remission without medical treatment. These psychological factors need to be taken into account when treating patients and developing a psychosocial education program aiming to improve QoL.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acromegaly; Growth hormone; Illness perceptions; Medication beliefs; Quality of life; Somatostatin analogs

Mesh:

Substances:

Year:  2015        PMID: 26164770     DOI: 10.1016/j.ghir.2015.06.008

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  3 in total

1.  Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Authors:  Roberto Salvatori; Pietro Maffei; Susan M Webb; Thierry Brue; Jane Loftus; Srinivas Rao Valluri; Roy Gomez; Michael P Wajnrajch; Maria Fleseriu
Journal:  Pituitary       Date:  2022-01-12       Impact factor: 4.107

2.  Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.

Authors:  Cecilia Follin; Sven Karlsson
Journal:  Endocr Connect       Date:  2016-07-25       Impact factor: 3.335

Review 3.  Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.

Authors:  P Maffei; F Dassie; S Camerini; A Wennberg; M Adriani; B Martin; R Vettor
Journal:  J Endocrinol Invest       Date:  2022-03-23       Impact factor: 5.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.